INSUBCONTINENT EXCLUSIVE:
India said it is testing samples of cough syrups produced by local manufacturer Maiden Pharmaceuticals for export after the World Health
Organization said its products were linked to the deaths of dozens of children in Gambia.The deaths of 66 children in the West African
products - Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup - had confirmed
ethylene glycol are used in antifreeze and brake fluids and other industrial applications but also as a cheaper alternative in some
reporters on Wednesday that the U.N
Controller General of India of the deaths late last month after which the regulator launched an investigation with state authorities in
tandem with the WHO.Naresh Kumar Goyal, a Maiden director, told Reuters, however, that the company had heard about the deaths only on
exported the syrup only to Gambia, the Indian health ministry said
Maiden on its website says it has two manufacturing plants, in Kundli and Panipat, both near New Delhi in Haryana, and has recently set up
another one.Maiden has an annual production capacity of 2.2 million syrup bottles, 600 million capsules, 18 million injections, 300,000
ointment tubes and 1.2 billion tablets.Maiden on its website says it sells its products at home and exports to countries in Asia, Africa and
Latin America, although Goyal said they were not currently selling in India.The health ministry said importing countries typically test such
products before allowing their use.Source: Reuters
This article first appeared/also appeared in https://adaderana.lk
